Atossa Therapeutics Receives Approval from the Swedish Ethics Review Authority to Initiate a Phase 2 Clinical Study of Oral Endoxifen to Reduce Mammographic Breast Density in Sweden

NEXT STORY
Board-Certified Internist and Renowned Professional Sports Team Physician, Dr. Michael S. Farber, Joins RNA Disease Diagnostics’ Advisory Board
PREV STORY
TCR² Therapeutics Receives FDA Orphan Drug Designation for Gavo-cel for the Treatment of Cholangiocarcinoma
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Asterias Biotherapeutics Announces Positive Outcome from Safety Review Committee for AST-VAC2; Recommends Continuation of Clinical Trial in Non-Small Cell Lung Cancer (NSCLC)

FREMONT, Calif., July 11, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a ...

author_avatar
NASDAQ Market News

Global Animal Health Market – Analysis By Animal Type, Product Type, By End User, By Region, By Country: Market Insights & Forecast with Impact of COVID-19

author_avatar
NASDAQ Market News

Myriad’s myPath® Melanoma Test Receives Medicare Coverage

author_avatar
NASDAQ Market News